Document Detail

Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
MedLine Citation:
PMID:  8260235     Owner:  NLM     Status:  MEDLINE    
173 patients with regional lymphatic metastases (n = 139) or distant disease (n = 34) were prospectively randomised, following resection of all clinically detectable tumour, to observation (n = 88) or adjuvant chemotherapy (n = 85). The treatment group received 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) 80 mg/m2 intravenously (i.v.) every 4 weeks, and actinomycin-D 10 micrograms/kg, vincristine 1.0 mg/m2 i.v. every 2 weeks for 6 months. The disease-free survival curves between the two groups were significantly different (P = 0.03). The estimated 5-year disease-free survival rate for the observation group was 9% and for the treatment group 29%. However, the overall survival curves were not significantly different for the two groups. Nitrosoureas may have a weak effect as adjuvant treatment in malignant melanoma.
C Karakousis; L Blumenson
Related Documents :
21883785 - Encouraging results in older patients receiving chemotherapy: a retrospective analysis ...
8188085 - A phase ii study of carboplatin and cisplatin in advanced or recurrent squamous carcino...
9923535 - Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic proge...
7915575 - Five-drug combination chemotherapy (fapel) for advanced gastric cancer: a pilot study.
3073655 - Clinical experience with cf-fura.
25443935 - The role of ultrasonography in predicting vesicoureteral reflux.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  29A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1993  
Date Detail:
Created Date:  1994-01-25     Completed Date:  1994-01-25     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1831-5     Citation Subset:  IM    
Surgical Oncology Department, Roswell Park Cancer Institute, Buffalo, New York 14263.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carmustine / administration & dosage
Dactinomycin / administration & dosage
Melanoma / drug therapy*,  mortality,  pathology
Middle Aged
Neoplasm Metastasis
Prospective Studies
Time Factors
Vincristine / administration & dosage
Reg. No./Substance:
154-93-8/Carmustine; 50-76-0/Dactinomycin; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sarcomatoid tumours of the breast in Denmark from 1977 to 1987. A clinicopathological and immunohist...
Next Document:  Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in...